Antibody-targeted photodynamic therapy

• US 20060231107A1
• Filed: 03/08/2004
• Published: 10/19/2006
• Est. Priority Date: 03/07/2003
• Status: Abandoned Application

• Current Assignee: George L. Mayo, Neeru C. Kumar, Randolph D. Glickman, Robert F. Melendez, Stuart J. Mckinnon
• Original Assignee: George L. Mayo, Neeru C. Kumar, Randolph D. Glickman, Robert F. Melendez, Stuart J. Mckinnon
• Inventors: Mayo, George L., Kumar, Neeru C., Glickman, Randolph D., Melendez, Robert F., McKinnon, Stuart J.
• Application Number:
  US10/548,183
• Publication Number:
  US 20060231107A1
• Time in Patent Office: Days
• US Class Current: 128/898
• CPC Class Codes: A61K 41/0057 Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
• CPC Class Codes: A61K 41/0071 PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
• CPC Class Codes: A61K 47/6803 Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
• CPC Class Codes: A61K 47/6849 the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• CPC Class Codes: A61P 27/02 Ophthalmic agents

Abstract

Disclosed are photosensitizer-antibody conjugates and methods for making such conjugates. Also disclosed are methods for using photosensitizer-antibody conjugates in photodynamic therapy to treat subjects with various diseases.

Claims

1. A method of treating a subject with ocular disease, comprising:

a. administering to the subject a conjugate of a benzoporphyrin and an anti-VEGF antibody; and

b. irradiating the subject with light, symptoms of the ocular disease being reduced as compared to a control lacking the conjugate.

2. The method of claim 1, wherein the benzophorphyrin is verteporfin.

3. The method of claim 2, wherein the verteporfin is VISUDYNE.

4. The method of claim 1, wherein the anti-VEGF antibody is a polyclonal antibody.

5. The method of claim 1, wherein the anti-VEGF antibody is a monoclonal antibody.

6. The method of claim 1, wherein the ocular disease is, characterized by neovascularization.

7. The method of claim 6, wherein the reduced symptom is neovascularization.

8. The method of claim 1, wherein the ocular disease is iris neovascularization.

9. The method of claim 1, wherein the ocular disease is corneal neovascularization.

10. The method of claim 1, wherein the ocular disease is choroidal neovascularization.

11. The method of claim 10, wherein the choroidal neovasculariztion is occult-choroidal neovascularization.

12. The method of claim 10, wherein the choroidal neovascularization is classic choroidal neovasculariztion.

13. The method of claim 1, wherein the ocular disease is proliferative diabetic retinopathy.

14. The method of claim 1, wherein administration is by intravenous injection of the conjugate.

15. The method of claim 1, wherein administration is by contact with an ophthalmic solution of the conjugate.

16. The method of claim 1, wherein the light is from about 600 nm to about 800 nm.

17. A photosensitizer-antibody conjugate, comprising VISUDYNE linked bound to an anti-VEGF polyclonal antibody.